Urinary p-Cresol in ASD
The etiology of autism encompasses a broad range of causative events, ranging from rare de novo high-penetrance mutations affecting genes such as NLGN3/4, SHANK3, NRXN1, and MECP2 to a complex mix of environmental and epigenetic factors acting upon a vulnerable genetic background. Increasing prevalence rates, decreasing heritability estimates, and polygenic models with multiple incompletely penetrant de novo mutations all suggest that in addition to broader diagnostic criteria and increased awareness, a real increase in incidence primarily due to greater gene-environment interactions may also be occurring. Notably, the phenotypic heterogeneity of ASD suggests the existence of many “autisms,” each characterized by specific etiopathogenetic underpinnings. Given the complex nature of this disorder, great effort is now under way aiming to define a reliable panel of biological markers able to assist clinicians in an early diagnosis. p-Cresol (4-methylphenol) belongs to the cresol class of organic aromatic compounds. Environmental p-cresol is absorbed through the gastrointestinal and the respiratory tracts, as well as through the intact skin. Physiological sources of p-cresol are represented by some gut bacteria which express synthetic enzymes not found in human cells. Urinary p-cresol or its conjugated derivative p-cresylsulfate holds the promise of representing one of these biomarkers in small autistic children and could contribute to identify a subgroup of ASD children characterized by greater severity, to better delineate abnormal gut function in autism and perhaps the entire pathophysiology of the disease in at least some individuals.
KeywordsAutism Spectrum Disorder Autism Spectrum Disorder Autistic Child Autistic Patient Autism Spectrum Disorder Child
- Cafaro V, Notomista E, Capasso P, Di Donato A. Mutation of glutamic acid 103 of toluene o-xylene monooxygenase as a means to control the catabolic efficiency of a recombinant upper pathway for degradation of methylated aromatic compounds. Appl Environ Microbiol. 2005;71:4744–50.PubMedCrossRefGoogle Scholar
- De Bruin A. Metabolism of occupational agents. In: Biochemical Toxicology of Environmental Agents. Amsterdam: Elsevier/North-Holland Biomedical Press; 1976. p. 87–170.Google Scholar
- Jyonouchi H, Geng L, Streck DL, et al. Children with autism spectrum disorders (ASD) who exhibit chronic gastrointestinal (GI) symptoms and marked fluctuation of behavioral symptoms exhibit distinct innate immune abnormalities and transcriptional profiles of peripheral blood (PB) monocytes. J Neuroimmunol. 2011;238:73–80.PubMedCrossRefGoogle Scholar
- Mandel HG. Pathways of drug biotransformation: biochemical conjugations. In: LaDu BN, Mandel HG, Way EL, editors. Pathways of drug biotransformation. Baltimore: Williams and Wilkins; 1971. p. 149–86.Google Scholar
- OECD. m-/p-Cresol category, screening information data set, initial assessment report. Paris: UNEP; 2003. www.chem.unep.ch/irptc/sids/oecdsids/m-p-cresols.pdf.
- Persico AM. Autisms. In: Rakic P, Rubenstein J, editors. Comprehensive developmental neuroscience. San Diego: Elsevier; 2012.Google Scholar
- Schopler E, Reichler RJ, Rochen Renner BR. The childhood autism rating scale for diagnostic screening and classification of autism. New York: Irvington; 1986.Google Scholar
- Shaw W. Increased urinary excretion of a 3-(3-hydroxy-phenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. In the gastrointestinal tract, in urine samples from patients with autism and schizophrenia. Nutr Neurosci. 2010;13:135–43.PubMedCrossRefGoogle Scholar